How to Qualify for Zepbound: Obesity, OSA, and the New 2024 Pathway

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• Zepbound is FDA-approved for adults with BMI 30+ or BMI 27+ with a comorbidity
• December 2024 OSA expansion added moderate-to-severe obstructive sleep apnea with obesity as a primary indication
• The OSA pathway opened partial Medicare coverage for tirzepatide that obesity-only criteria did not
• Categorical exclusions: MTC history, MEN-2, pregnancy, severe hypersensitivity
• Insurance documentation typically requires BMI calculation, comorbidity proof, and lifestyle intervention records

Direct answer

To qualify for Zepbound, you must be an adult 18 or older with BMI 30 or higher, OR BMI 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, obstructive sleep apnea). The December 2024 FDA expansion added moderate-to-severe OSA with obesity as a primary indication, which created a distinct insurance pathway. Patients with personal or family history of medullary thyroid carcinoma, MEN-2, pregnancy, severe hypersensitivity to tirzepatide, or active pancreatitis are excluded categorically.

Table of contents

1. The two qualifying pathways
2. BMI calculation and thresholds
3. Qualifying comorbidities under the 27+ rule
4. The OSA pathway (December 2024 expansion)
5. The SURMOUNT-OSA evidence base
6. Insurance documentation requirements
7. Medicare and the OSA pathway
8. Disqualifying conditions
9. Switching to Zepbound from another GLP-1
10. Contrary view: should the BMI threshold be lower
11. Decision framework
12. FAQ
13. Sources

The two qualifying pathways

Zepbound has two primary FDA-approved indications:

1. Obesity (November 2023): Adults with BMI 30+ or BMI 27+ with at least one weight-related comorbidity, as an adjunct to reduced-calorie diet and increased physical activity.
2. Obstructive sleep apnea with obesity (December 2024): Adults with moderate-to-severe OSA and obesity (BMI 30+), as an adjunct to a reduced-calorie diet and increased physical activity.

These pathways are not mutually exclusive. A patient with BMI 32 and documented OSA could qualify under either route. The pathway choice matters for insurance coverage, particularly Medicare.

BMI calculation and thresholds

BMI = weight (kg) divided by height (m) squared. Online calculators are reliable. Categories used in adult Zepbound qualification:

BMI	Category	Zepbound Eligible
Under 27	Below threshold	No
27.0-29.9	Overweight	Yes, if at least one comorbidity is documented
30.0-34.9	Class 1 obesity	Yes
35.0-39.9	Class 2 obesity	Yes
40+	Class 3 obesity (severe)	Yes; bariatric surgery also considered

BMI is an imperfect measure. Heavily muscled patients may have BMI 27+ without metabolic risk. Patients with significant central adiposity may have metabolic disease at lower BMI than the cutoff suggests. The FDA threshold is the operational gate, not the only signal of metabolic health.

Qualifying comorbidities under the 27+ rule

FDA-recognized comorbidities that qualify a patient with BMI 27-29.9 for Zepbound:

• Hypertension: Blood pressure 130/80 or higher confirmed on multiple readings, or current antihypertensive use
• Dyslipidemia: Elevated LDL, low HDL, elevated triglycerides, or current lipid-lowering medication
• Type 2 diabetes: HbA1c 6.5% or higher; patients in this group might prefer Mounjaro for the diabetes-focused insurance pathway
• Cardiovascular disease: History of myocardial infarction, stroke, heart failure, or coronary artery disease
• Obstructive sleep apnea: Documented by polysomnography or home sleep apnea test, AHI 5+ per hour

Some insurance plans accept additional comorbidities:

• Nonalcoholic fatty liver disease with elevated liver enzymes or imaging findings
• Polycystic ovary syndrome
• Prediabetes (HbA1c 5.7-6.4%)
• Severe gastroesophageal reflux requiring chronic PPI therapy
• Obesity-related osteoarthritis

The OSA pathway (December 2024 expansion)

The FDA expanded Zepbound on December 20, 2024 to include moderate-to-severe obstructive sleep apnea with obesity as a primary indication. The criteria:

• Adult age 18+
• Moderate-to-severe OSA (AHI 15 or higher, or AHI 5+ with daytime symptoms)
• BMI 30 or higher (obesity)
• Used as adjunct to reduced-calorie diet and increased physical activity

This expansion mattered because it created a non-obesity-only insurance pathway. Medicare Part D excludes coverage for drugs prescribed solely for weight loss, but the OSA indication is not weight loss in label terms; it is treatment of OSA. This shifted coverage for some patients with documented OSA and obesity who could not access Zepbound under the obesity-only label.

The SURMOUNT-OSA evidence base

The pivotal trial for the OSA expansion was SURMOUNT-OSA (Malhotra et al. 2024, NEJM). Design summary:

• Population: 469 adults with moderate-to-severe OSA and obesity, split into two studies (one on PAP therapy, one not)
• Intervention: tirzepatide 10 or 15 mg weekly versus placebo
• Duration: 52 weeks
• Primary outcome: change in apnea-hypopnea index (AHI)

Results: tirzepatide produced a mean AHI reduction of approximately 25 events per hour in the non-PAP group and approximately 30 events per hour in the PAP group, versus minimal change with placebo. About half of tirzepatide-treated patients met criteria for OSA remission. Weight loss in the trial averaged 18-20% body weight.

The trial supported FDA expansion. Whether OSA improvement is independent of weight loss or driven by it remains debated; the practical reality is that tirzepatide-mediated weight loss substantially improved OSA severity.

Insurance documentation requirements

For the obesity pathway:

1. Current BMI calculation with documented height and weight
2. Comorbidity documentation if BMI 27-29.9 (lab results, ICD-10 codes, specialist notes)
3. Prior lifestyle intervention attempt (often 3-6 months documented)
4. Sometimes: prior pharmacotherapy trial (phentermine, topiramate, or other approved weight-loss medication)
5. Confirmation of no contraindications

For the OSA pathway:

1. Sleep study report documenting AHI 15+ or AHI 5+ with daytime symptoms
2. BMI documentation (30+ required)
3. Sometimes: documentation of PAP therapy trial and tolerance, particularly for Medicare
4. Comorbidity-style step therapy may apply
5. Confirmation of no contraindications

Medicare and the OSA pathway

Medicare Part D historically excluded coverage for weight-loss medications under a statutory carve-out. The December 2024 OSA expansion changed coverage for some patients:

• Zepbound for obesity alone: still excluded from most Medicare Part D coverage
• Zepbound for OSA with obesity: covered by Medicare Part D when the OSA diagnosis is the primary indication submitted

The practical effect: Medicare patients with documented OSA and BMI 30+ can sometimes obtain Zepbound coverage that they could not under the obesity-only label. Plans vary in how strictly they verify the OSA indication; some require sleep study documentation, others accept the OSA diagnosis code.

Wegovy (semaglutide) received a similar coverage expansion under its cardiovascular indication after the SELECT trial. Patients with established cardiovascular disease and BMI 27+ can sometimes obtain Wegovy coverage through Medicare.

Disqualifying conditions

Absolute disqualifications:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Pregnancy or planned pregnancy within 2 months
• Severe hypersensitivity to tirzepatide
• Active pancreatitis

Relative disqualifications:

• Prior pancreatitis
• Severe gastroparesis
• Active eating disorder
• Active gallbladder disease
• BMI under 27 (does not meet FDA threshold)
• Age under 18 (Zepbound not approved for pediatric use)
• Severe diabetic retinopathy without ophthalmology clearance

Switching to Zepbound from another GLP-1

Common scenarios:

From Wegovy (semaglutide): Patients with inadequate weight loss on Wegovy maximum dose (2.4 mg) sometimes switch to tirzepatide. Tirzepatide produces greater mean weight loss than semaglutide in head-to-head trial data (SURMOUNT-1 ~22.5% at 15 mg vs. STEP 1 ~14.9% at 2.4 mg). Switch typically starts at Zepbound 2.5 mg weekly with standard titration regardless of prior semaglutide dose.

From Saxenda (liraglutide): Liraglutide is daily; tirzepatide is weekly. The switch is usually straightforward, with last liraglutide dose followed by first Zepbound dose 1-2 days later.

From Ozempic (off-label weight loss): Patients on off-label Ozempic for weight loss often switch to Zepbound for both the labeled indication (improving insurance coverage) and the dose ceiling (Zepbound goes up to 15 mg; Ozempic stops at 2 mg).

From compounded semaglutide: Sometimes patients switch to brand Zepbound for FDA-approved status. Sometimes the reverse, for cost. Clinical judgment guides the decision.

Contrary view: should the BMI threshold be lower

Some arguments for lower thresholds:

Metabolic risk does not start at BMI 30. Insulin resistance, dyslipidemia, and elevated cardiovascular risk often begin at BMI 25-27. Restricting GLP-1 to BMI 30+ may exclude patients who would benefit metabolically.

Ethnic differences in body composition. South Asian, East Asian, and some Hispanic populations develop metabolic complications at lower BMI. The WHO 2004 recommendation for Asian-adjusted BMI categories (overweight at 23+, obesity at 27.5+) has not been incorporated into US FDA criteria.

Counter-arguments:

Side effect profile favors selective use. Tirzepatide carries real risks (pancreatitis, gallbladder events, lean mass loss). Wider eligibility increases population exposure to risks that the trials studied in higher-BMI populations.

Supply constraints. Expanding eligibility while supply is limited would crowd out higher-BMI patients with greater absolute risk reduction potential.

The reasonable position: maintain the FDA threshold as the operational gate, allow clinician discretion for off-label use in patients with documented metabolic risk at lower BMI, and continue research into individualized criteria beyond BMI alone.

Decision framework

BMI 30+ without sleep apnea: Standard obesity pathway. Document lifestyle attempt and submit prior authorization.

BMI 30+ with documented OSA: Consider the OSA pathway, especially if you have Medicare. Submit sleep study results with prior authorization.

BMI 27-29.9 with hypertension, dyslipidemia, T2D, OSA, or CVD: Obesity pathway with comorbidity documentation.

BMI 27-29.9 without listed comorbidity: Generally not eligible under FDA criteria. Compounded path is an option through some platforms with documented clinical need.

BMI under 27: Not eligible under FDA criteria. Lifestyle and behavioral interventions are the appropriate focus.

Boxed warning positive: Not eligible regardless of pathway.

FAQ

How do I qualify for Zepbound? Adult, BMI 30+ or 27+ with comorbidity, no contraindications. The 2024 OSA expansion added moderate-to-severe OSA with obesity as a primary indication.

What BMI do I need for Zepbound? 30+ qualifies without additional conditions. 27-29.9 qualifies with a comorbidity. Below 27 does not qualify under FDA criteria.

Does sleep apnea qualify me for Zepbound? Yes, as of December 2024. Moderate-to-severe OSA with BMI 30+ is a primary indication.

How is qualification documented for insurance? BMI calculation, comorbidity documentation, lifestyle intervention records, confirmation of no contraindications. The OSA pathway requires sleep study results.

Does Medicare cover Zepbound? Not for obesity alone. Yes for the OSA indication with documented OSA and BMI 30+.

Can I qualify if I just want to lose weight cosmetically? No. FDA criteria require BMI 30+ or 27+ with comorbidity. Reputable platforms decline patients below threshold.

What disqualifies me from Zepbound? MTC history, MEN-2, pregnancy, severe hypersensitivity, active pancreatitis. Relative: prior pancreatitis, severe gastroparesis, active eating disorder, BMI below 27.

Can I switch from Wegovy to Zepbound? Yes, with clinician supervision. Start at Zepbound 2.5 mg or 5 mg regardless of prior Wegovy dose. No washout period required.

Sources

1. FDA. Zepbound Prescribing Information, including OSA Indication. Current revision 2025.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
3. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). NEJM. 2024.
4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
5. FDA. Press Release: Zepbound Approved for Obstructive Sleep Apnea in Adults with Obesity. December 2024.
6. Centers for Medicare and Medicaid Services. Part D Coverage of Anti-Obesity Drugs: Statutory Exclusion and OSA Indication Update. 2025.
7. American Academy of Sleep Medicine. AASM Clinical Guidelines for Diagnostic Testing of OSA. 2024 update.
8. Eli Lilly. LillyDirect Self Pay Journey Program: Zepbound Vial Pricing and Eligibility. 2025.
9. Endocrine Society. Pharmacological Management of Obesity: Clinical Practice Guideline. 2023 update.
10. American Association of Clinical Endocrinologists. Adiposity-Based Chronic Disease Framework Position Statement. 2024.
11. WHO Expert Consultation. Appropriate body-mass index for Asian populations. Lancet. 2004.
12. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). NEJM. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with independent licensed clinicians and U.S.-based pharmacies. Qualification decisions are made by independent providers based on clinical evaluation. Insurance prior authorization criteria vary by plan.

Compounded Medication Notice. Compounded tirzepatide is prepared by a state-licensed 503A pharmacy in response to an individual prescription. It is not FDA-approved and is not interchangeable with brand Zepbound or Mounjaro.

Results Disclaimer. Trial outcomes cited (SURMOUNT-1, SURMOUNT-OSA, SURMOUNT-4) reflect average results in trial populations. Individual outcomes vary based on adherence, baseline weight, comorbidity profile, and concurrent therapy.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are trademarks of Novo Nordisk. Saxenda is a trademark of Novo Nordisk. FormBlends is not affiliated with these manufacturers.